Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cartesian Therapeutics (RNAC) Debt Ratio (2016 - 2023)

Historic Debt Ratio for Cartesian Therapeutics (RNAC) over the last 9 years, with Q4 2023 value amounting to 0.09.

  • Cartesian Therapeutics' Debt Ratio fell 4138.55% to 0.09 in Q4 2023 from the same period last year, while for Dec 2023 it was 0.09, marking a year-over-year decrease of 4138.55%. This contributed to the annual value of 0.09 for FY2023, which is 4138.55% down from last year.
  • Latest data reveals that Cartesian Therapeutics reported Debt Ratio of 0.09 as of Q4 2023, which was down 4138.55% from 0.17 recorded in Q2 2023.
  • Cartesian Therapeutics' Debt Ratio's 5-year high stood at 0.53 during Q3 2019, with a 5-year trough of 0.09 in Q4 2023.
  • Its 5-year average for Debt Ratio is 0.2, with a median of 0.16 in 2021.
  • In the last 5 years, Cartesian Therapeutics' Debt Ratio skyrocketed by 5890.31% in 2019 and then tumbled by 7432.88% in 2020.
  • Cartesian Therapeutics' Debt Ratio (Quarter) stood at 0.19 in 2019, then dropped by 21.07% to 0.15 in 2020, then increased by 6.98% to 0.16 in 2021, then fell by 1.26% to 0.16 in 2022, then tumbled by 41.39% to 0.09 in 2023.
  • Its last three reported values are 0.09 in Q4 2023, 0.17 for Q2 2023, and 0.17 during Q1 2023.